Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opemalirsen
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Opemalirsen is an investigational antisense oligonucleotide (ASO) developed by AstraZeneca and Ionis Pharmaceuticals. It is designed to reduce the production of apolipoprotein L1 (APOL1) for the treatment of APOL1-mediated kidney disease (AMKD). The drug is administered via subcutaneous injection and is currently undergoing clinical trials to assess its efficacy, safety, and tolerability.
- Other names
- ION532ION-532ION 532IONIS-AZ5-2.5RxIONIS-AZ-5-2.5RxIONIS-AZ 5-2.5Rx
02
Targets
APOL1 (Apolipoprotein L1)
Beyond the preview
Go deeper on opemalirsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opemalirsen.